<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04790084</url>
  </required_header>
  <id_info>
    <org_study_id>3DCVICFD</org_study_id>
    <nct_id>NCT04790084</nct_id>
  </id_info>
  <brief_title>Three-dimensional Choroidal Vascularity Index in Common Fundus Diseases</brief_title>
  <official_title>Changes of Three-dimensional Choroidal Vascular Index by Optical Coherence Tomography in Common Fundus Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Renmin Hospital of Wuhan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Renmin Hospital of Wuhan University</source>
  <brief_summary>
    <textblock>
      Explore the changes of choroidal blood perfusion in common fundus diseases by&#xD;
      three-dimensional choroidal vascularity index, an optical coherence tomography (OCT)&#xD;
      parameter.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Compared with the choroidal vascularity index on a single OCT image, the three-dimensional&#xD;
      choroidal vascularity index can evaluate the choroidal changes of chorioretinal diseases as a&#xD;
      whole. In this study, the choroidal changes of patients with common fundus diseases were&#xD;
      systematically evaluated by collecting OCT and optical coherence tomography angiography&#xD;
      (OCTA) images of patients with common fundus diseases, especially in healthy people, myopic&#xD;
      people and patients with central serous chorioretinopathy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 4, 2021</start_date>
  <completion_date type="Anticipated">March 10, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 10, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Three-dimensional choroidal vascularity index</measure>
    <time_frame>baseline, pre-intervention</time_frame>
    <description>Three-dimensional choroidal vascularity index of healthy people and patients with common fundus diseases, based on optical coherence tomography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Choriocapillaris flow deficits%</measure>
    <time_frame>baseline, pre-intervention</time_frame>
    <description>Choriocapillaris flow deficits% of healthy people and patients with common fundus diseases, based on optical coherence tomography angiography.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Choroid</condition>
  <arm_group>
    <arm_group_label>Healthy-Myopia-CSC</arm_group_label>
    <description>Cross-sectional study, no intervention, only collecting OCT,OCTA images and other eye parameters of patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>no intervention</description>
    <arm_group_label>Healthy-Myopia-CSC</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        1. Healthy participants (1) Inclusion Criteria: 1) without systemic diseases such as&#xD;
             diabetes and hypertension 2) best corrected visual acuity BCVA ≥ 1.0 3) aged 18 years&#xD;
             or older (2) Exclusion criteria: 1) equivalent spherical refraction between -3&#xD;
             diopters and + 1.0 diopters 2) any visible lesions in the retina, optic nerve, or&#xD;
             choroid 3) history of refractive or intraocular surgery&#xD;
&#xD;
          2. Myopia group (1) Inclusion Criteria: 1) equivalent spherical refraction greater than&#xD;
             -0.25 diopters 2) without systemic diseases such as diabetes and hypertension 3) Best&#xD;
             corrected visual acuity (BCVA) ≥ 1.0 4) aged 10 years or older (2) Exclusion criteria:&#xD;
             1) history of refractive or intraocular surgery 2) history of laser therapy 3) other&#xD;
             systemic diseases that may affect the choroid&#xD;
&#xD;
          3. Central serous chorioretinopathy (CSC) group (1) Inclusion Criteria: 1) a diagnosis of&#xD;
             CSC (2) Exclusion criteria: 1) high myopia or hyperopia (greater than 26 or +3&#xD;
             diopters of refractive error) 3) other systemic diseases that may affect the choroid&#xD;
             4) any other associated retinal pathology 5) history of refractive or intraocular&#xD;
             surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>CZ Chen, PHD</last_name>
    <phone>13072765173</phone>
    <email>whuchenchzh@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>GP Sun, MD</last_name>
    <phone>15827084278</phone>
    <email>sungongpeng@whu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CZ Chen, PHD</last_name>
      <phone>+86 13072765173</phone>
      <email>whuchenchzh@163.com</email>
    </contact>
    <contact_backup>
      <last_name>GP Sun</last_name>
      <phone>15827084278</phone>
      <email>sungongpeng@whu.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Zhen Chen, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 3, 2021</study_first_submitted>
  <study_first_submitted_qc>March 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>March 6, 2021</last_update_submitted>
  <last_update_submitted_qc>March 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Renmin Hospital of Wuhan University</investigator_affiliation>
    <investigator_full_name>Changzheng Chen</investigator_full_name>
    <investigator_title>Chief of Department of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>choroidal vascularity index</keyword>
  <keyword>fundus disease</keyword>
  <keyword>choroidal blood flow</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

